Low Molecular Weight Heparin (Enoxaparin) Versus Oral Anticoagulant Therapy (Acenocoumarol) in the Long-Term Treatment of Deep Venous Thrombosis in the Elderly: a Randomized Trial
- 1 January 2000
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (10), 559-564
- https://doi.org/10.1055/s-0037-1614067
Abstract
This study aims to establish the relative effectiveness and safety of low molecular weight heparin in elderly patients with venous thrombosis in order to find an alternative to oral anticoagulant therapy with less bleeding complications in the long-term treatment of deep venous thrombosis (DVT). One hundred consecutive elderly patients (>75 years old) with venographically demonstrated proximal DVT were included in a randomized trial. All patients were treated for ten days with adjusted doses of intravenous heparin. Informed consent was obtained and on the eight day, patients were randomly allocated to receive acenocoumarol (INR 2.0-3.0) or subcutaneous enoxaparin (4000 anti-Xa units once a day) for three months. All patients were followed-up clinically and venographically for a one year period. The results were analyzed with Fisher’s exact test or chi-square test as appropriate. During the treatment and surveillance period, 6 of the 50 patients (12%) who received acenocoumarol and 8 of the 50 patients (16%) who received enoxaparin had new episodes of venous thromboembolism confirmed by objective testing (p = 0.6; 95% CI for the difference: −19.5 to 11.5). Hemorrhagic complications occurred in six of the 50 patients (12%) who received acenocoumarol and in one (2%) of those on enoxaparin (p = 0.1; 95% CI for the difference: -1.8 to 21.8). Vertebral fractures developed in 2 patients (4%) in the enoxaparin group (p = 0.5; 95% CI for the diference: −11.4 to 3.4). These results show that fixed dose enoxaparin seems to be effective and safe in the long-term treatment of proximal DVT in the elderly. In comparison with oral anticoagulants, the findings are inconclusive due to the wide confidence intervals for differences between outcomes, however they suggest that the former may have less bleeding complications with similar efficacy. * F. Veiga is presently Head of Department of Geriatrics, Complexo Hospitalario Xeral-Calde, Lugo, Spain.Keywords
This publication has 16 references indexed in Scilit:
- Hemorrhagic Complications of Anticoagulant TreatmentChest, 1998
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 1998
- Low‐Molecular‐Weight Heparin versus Warfarin for Prevention of Recurrent Venous Thromboembolism: A Randomized TrialWorld Journal of Surgery, 1996
- The Optimal Duration of Anticoagulant Therapy for Venous ThrombosisNew England Journal of Medicine, 1995
- Deep-Vein ThrombosisNew England Journal of Medicine, 1994
- The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge.Circulation, 1983
- Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1982
- Adjusted Subcutaneous Heparin versus Warfarin Sodium in the Long-Term Treatment of Venous ThrombosisNew England Journal of Medicine, 1982
- Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous ThrombosisNew England Journal of Medicine, 1979
- Studies of Illness in the AgedJAMA, 1963